NASDAQ:MRTX Mirati Therapeutics (MRTX) Stock Forecast, Price & News $41.00 +4.50 (+12.33%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$36.53▼$41.0850-Day Range$27.80▼$39.9652-Week Range$27.30▼$101.30Volume4.79 million shsAverage Volume1.16 million shsMarket Capitalization$2.40 billionP/E RatioN/ADividend YieldN/APrice Target$55.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Mirati Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside35.8% Upside$55.67 Price TargetShort InterestBearish16.14% of Shares Sold ShortDividend StrengthN/ASustainability-0.68Upright™ Environmental ScoreNews Sentiment0.37Based on 2 Articles This WeekInsider TradingAcquiring Shares$33.70 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($11.85) to ($10.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector217th out of 968 stocksPharmaceutical Preparations Industry84th out of 445 stocks 4.3 Analyst's Opinion Consensus RatingMirati Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.67, Mirati Therapeutics has a forecasted upside of 35.8% from its current price of $41.00.Amount of Analyst CoverageMirati Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.14% of the outstanding shares of Mirati Therapeutics have been sold short.Short Interest Ratio / Days to CoverMirati Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Mirati Therapeutics has recently decreased by 1.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMirati Therapeutics does not currently pay a dividend.Dividend GrowthMirati Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirati Therapeutics has received a 74.62% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirati Therapeutics is -0.68. Previous Next 1.9 News and Social Media Coverage News SentimentMirati Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Mirati Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for MRTX on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows4 people have added Mirati Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirati Therapeutics insiders have bought 39,507.94% more of their company's stock than they have sold. Specifically, they have bought $33,700,022.00 in company stock and sold $85,084.00 in company stock.Percentage Held by InsidersOnly 3.47% of the stock of Mirati Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirati Therapeutics are expected to grow in the coming year, from ($11.85) to ($10.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirati Therapeutics is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirati Therapeutics is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirati Therapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mirati Therapeutics (NASDAQ:MRTX) StockMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Read More MRTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRTX Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comMirati Therapeutics (NASDAQ:MRTX) Shares Gap Down to $34.05September 13, 2023 | benzinga.comMassive Insider Trade At Mirati TherapeuticsSeptember 22, 2023 | Chaikin Analytics (Ad)"This Could be the Biggest Stock Story of 2023"A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.September 13, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Mirati Therapeutics (MRTX) and Opthea Limited Sponsored ADR (OPT)September 11, 2023 | markets.businessinsider.comScotiabank Keeps Their Sell Rating on Mirati Therapeutics (MRTX)August 29, 2023 | finance.yahoo.comMirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 28, 2023 | msn.comMirati: Expansion Of Adagrasib With sNDA And Combination StudiesAugust 23, 2023 | marketwatch.comMirati Therapeutics Taps Aaron Ondrey as CFO to Succeed Laurie StelzerSeptember 22, 2023 | Chaikin Analytics (Ad)"This Could be the Biggest Stock Story of 2023"A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.August 23, 2023 | markets.businessinsider.comMirati Therapeutics CFO Laurie Stelzer ResignsAugust 23, 2023 | msn.comMirati CFO leaving company in wake of CEO departureAugust 22, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Mirati Therapeutics (MRTX)August 19, 2023 | finance.yahoo.com3 Under-the-Radar Biotech Stocks to Buy in 2023August 16, 2023 | finance.yahoo.comBOXER CAPITAL, LLC Boosts Stake in Mirati Therapeutics IncAugust 11, 2023 | msn.comCiti upgrades Mirati to buy; cites valuation, leadership changeAugust 11, 2023 | msn.comB. Riley Securities Upgrades Mirati Therapeutics (MRTX)August 10, 2023 | seekingalpha.comMirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 9, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Mirati Therapeutics (MRTX)August 9, 2023 | msn.comMirati Rockets 26% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO ExitAugust 9, 2023 | markets.businessinsider.comMirati Therapeutics (MRTX) Has a New Rating from BarclaysAugust 9, 2023 | markets.businessinsider.comBank of America Securities Sticks to Their Hold Rating for Mirati Therapeutics (MRTX)August 9, 2023 | msn.comMirati Therapeutics up 9% on pricing $300M upsized equity offeringAugust 9, 2023 | finance.yahoo.comMirati Therapeutics Announces Pricing of Upsized Public OfferingAugust 8, 2023 | finance.yahoo.comMirati Therapeutics Announces Departure of Chief Executive Officer David MeekAugust 8, 2023 | finance.yahoo.comMirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesAugust 8, 2023 | finance.yahoo.comMirati Therapeutics Announces Proposed Public OfferingAugust 3, 2023 | msn.comMirati Therapeutics (MRTX) Price Target Decreased by 13.20% to 58.68See More Headlines Receive MRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRTX Company Calendar Last Earnings8/08/2023Today9/22/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRTX CUSIPN/A CIK1576263 Webwww.mirati.com Phone(858) 332-3410FaxN/AEmployees587Year Founded2013Price Target and Rating Average Stock Price Forecast$55.67 High Stock Price Forecast$83.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+36.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($12.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-740,870,000.00 Net Margins-2,709.33% Pretax Margin-2,707.47% Return on Equity-79.37% Return on Assets-66.23% Debt Debt-to-Equity RatioN/A Current Ratio5.85 Quick Ratio5.79 Sales & Book Value Annual Sales$12.44 million Price / Sales192.52 Cash FlowN/A Price / Cash FlowN/A Book Value$17.31 per share Price / Book2.36Miscellaneous Outstanding Shares58,600,000Free Float56,570,000Market Cap$2.39 billion OptionableOptionable Beta0.91 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Charles M. Baum M.D. (Age 65)Ph.D., Founder, Interim CEO, Pres, Head of R&D and Director Comp: $1.07MMs. Laurie D. Stelzer M.B.A. (Age 55)CFO & Principal Financial and Accounting Officer Comp: $609.06kDr. James G. Christensen Ph.D. (Age 55)Exec. VP & Chief Scientific Officer Comp: $1.76MDr. Alan Bart Sandler M.D. (Age 66)Exec. VP & Chief Medical Officer Comp: $591kMr. John B. Moriarty Jr. (Age 55)J.D., Chief Legal Officer Mr. Michael E. Paolucci (Age 63)Chief People Officer Mr. Benjamin J. Hickey M.B.A. (Age 48)Chief Commercial Officer Dr. Kelly Covello Ph.D.VP & Head of Medical AffairsMr. Ryan AsayVP & Head of Corp. AffairsMr. Aaron Ondrey (Age 47)Sr. VP of Financial Planning & Analysis More ExecutivesKey CompetitorsPTC TherapeuticsNASDAQ:PTCTRocket PharmaceuticalsNASDAQ:RCKTDynavax TechnologiesNASDAQ:DVAXCureVacNASDAQ:CVACIDEAYA BiosciencesNASDAQ:IDYAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 37,989 shares on 9/21/2023Ownership: 0.177%Jamie ChristensenSold 2,388 sharesTotal: $85,084.44 ($35.63/share)Comerica BankBought 14,519 shares on 8/22/2023Ownership: 0.025%Virginia Retirement Systems ET ALBought 6,600 shares on 8/22/2023Ownership: 0.011%California State Teachers Retirement SystemSold 1,018 shares on 8/21/2023Ownership: 0.087%View All Insider TransactionsView All Institutional Transactions MRTX Stock - Frequently Asked Questions Should I buy or sell Mirati Therapeutics stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRTX shares. View MRTX analyst ratings or view top-rated stocks. What is Mirati Therapeutics' stock price forecast for 2023? 12 Wall Street research analysts have issued 1 year price targets for Mirati Therapeutics' stock. Their MRTX share price forecasts range from $31.00 to $83.00. On average, they predict the company's stock price to reach $55.67 in the next twelve months. This suggests a possible upside of 36.2% from the stock's current price. View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts. How have MRTX shares performed in 2023? Mirati Therapeutics' stock was trading at $45.31 on January 1st, 2023. Since then, MRTX stock has decreased by 9.8% and is now trading at $40.87. View the best growth stocks for 2023 here. When is Mirati Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our MRTX earnings forecast. How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($3.04) EPS for the quarter, topping the consensus estimate of ($3.23) by $0.19. The biotechnology company had revenue of $13.70 million for the quarter, compared to the consensus estimate of $13.17 million. Mirati Therapeutics had a negative trailing twelve-month return on equity of 79.37% and a negative net margin of 2,709.33%. The company's revenue for the quarter was up 153.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($3.18) EPS. What other stocks do shareholders of Mirati Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU). What is Mirati Therapeutics' stock symbol? Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX." Who are Mirati Therapeutics' major shareholders? Mirati Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.66%), State Street Corp (4.41%), Camber Capital Management LP (3.07%), Rock Springs Capital Management LP (1.91%), Candriam S.C.A. (1.50%) and Assenagon Asset Management S.A. (1.39%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Faheem Hasnain, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Laurie Stelzer, Ltd Braslyn, Maria E Martinez and Vickie S Reed. View institutional ownership trends. How do I buy shares of Mirati Therapeutics? Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mirati Therapeutics' stock price today? One share of MRTX stock can currently be purchased for approximately $40.87. How much money does Mirati Therapeutics make? Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.39 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.82) on an earnings per share basis. How many employees does Mirati Therapeutics have? The company employs 587 workers across the globe. Does Mirati Therapeutics have any subsidiaries? The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..Read More How can I contact Mirati Therapeutics? Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com. This page (NASDAQ:MRTX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.